Post #961 by OrmontUS on the Macroeconomic Trends and Risks board

Personal Finance Topics / Macroeconomic Trends and Risks

Unthreaded | Threaded | Whole Thread (14)

Post New | Post Reply | Report Post | Recommend It!

No. of Recommendations: 1

The company said external price estimates were based on assumptions of higher use of HIV prevention drugs than currently, or projected. It said global price planning was in progress and would take into account “nearly two decades of research and development, constant learning and iteration, and manufacturing investments to deliver lenacapavir at scale”.

While it's tempting to say "give it away", I wounder if you do a current-value, not only of the 20 year's worth of work on this drug, but also the prorated costs of dry runs which failed, how you would amortize the costs into the price.

Jeff

Post New | Post Reply | Report Post | Recommend It!

Print the post

Unthreaded | Threaded | Whole Thread (14)

Prev | Next

Announcements

Macroeconomic Trends and Risks FAQ

Contact Shrewd'm
Contact the developer of these message boards.

A community forum supporting civilized, and highly helpful, self-educating investors that come together for Shrewdness and merry spirits. These message boards closely follow the look and feel of the old message boards at boards.fool.com prior to the boards redirected to discussion.fool.com. Shrewd'm is not affiliated with the comprehensive and excellent investment website, The Motley Fool (TMF), in any way. The Shrewd commmunity here has owed, and continues to owe, gratitude to The Motley Fool for nurturing a culture of jovial irreverence towards Wall St, and that tradition will continue here.